Abstract
1 The concentrations of cyclophosphamide in plasma and saliva were determined in seven patients following administration of single doses of cyclophosphamide during chemotherapy for lymphoma. 2 The saliva/plasma ratio was 0.77 +/- 0.24 (s.d.) and showed no time-dependence being rapidly established following intravenous and oral administration. 3 The T 1/2 of cyclophosphamide (8.38 +/- 2.25 h) determined from salivary measurements was not significantly different from that in plasma (8.24 +/- 2.60 h). It was not possible to estimate the apparent volume of distribution or total body clearance utilizing the salivary cyclophosphamide concentration without appropriate correction for the saliva/plasma concentration ratio. 4 The binding to the plasma protein of normal plasma of cyclophosphamide was 13.4 +/- 5.3%. The Scatchard plot for binding to bovine serum albumin indicates only weak binding to non-specific sites. 5 Salivary cyclophosphamide therefore indicates the concentration of the unbound fraction of plasma cyclophosphamide.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bagley C. M., Jr, Bostick F. W., DeVita V. T., Jr Clinical pharmacology of cyclophosphamide. Cancer Res. 1973 Feb;33(2):226–233. [PubMed] [Google Scholar]
- Danhof M., Breimer D. D. Therapeutic drug monitoring in saliva. Clin Pharmacokinet. 1978 Jan-Feb;3(1):39–57. doi: 10.2165/00003088-197803010-00003. [DOI] [PubMed] [Google Scholar]
- Duncan J. H., Colvin O. M., Fenselau C. Mass spectrometric study of the distribution of cyclophosphamide in humans. Toxicol Appl Pharmacol. 1973 Feb;24(2):317–323. doi: 10.1016/0041-008x(73)90151-8. [DOI] [PubMed] [Google Scholar]
- Galeazzi R. L., Benet L. Z., Sheiner L. B. Relationship between the pharmacokinetics and pharmacodynamics of procainamide. Clin Pharmacol Ther. 1976 Sep;20(3):278–289. doi: 10.1002/cpt1976203278. [DOI] [PubMed] [Google Scholar]
- Horning M. G., Brown L., Nowlin J., Lertratanangkoon K., Kellaway P., Zion T. E. Use of saliva in therapeutic drug monitoring. Clin Chem. 1977 Feb;23(2 Pt 1):157–164. [PubMed] [Google Scholar]
- Jardine I., Fenselau C., Appler M., Kan M. N., Brundrett R. B., Colvin M. Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy. Cancer Res. 1978 Feb;38(2):408–415. [PubMed] [Google Scholar]
- Juma F. D., Rogers H. J., Trounce J. R., Bradbrook I. D. Pharmacokinetics of intravenous cyclophosphamide in man, estimated by gas-liquid chromatography. Cancer Chemother Pharmacol. 1978;1(4):229–231. doi: 10.1007/BF00257155. [DOI] [PubMed] [Google Scholar]
- Koysooko R., Ellis E. F., Levy G. Relationship between theophylline concentration in plasma and saliva of man. Clin Pharmacol Ther. 1974 May;15(5):454–460. doi: 10.1002/cpt1974155454. [DOI] [PubMed] [Google Scholar]